Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OCS logo OCS
Upturn stock ratingUpturn stock rating
OCS logo

Oculis Holding AG Ordinary shares (OCS)

Upturn stock ratingUpturn stock rating
$16.35
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: OCS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $37.55

1 Year Target Price $37.55

Analysts Price Target For last 52 week
$37.55 Target price
52w Low $11.56
Current$16.35
52w High $23.08

Analysis of Past Performance

Type Stock
Historic Profit 23.68%
Avg. Invested days 45
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 855.69M USD
Price to earnings Ratio -
1Y Target Price 37.55
Price to earnings Ratio -
1Y Target Price 37.55
Volume (30-day avg) 7
Beta 0.12
52 Weeks Range 11.56 - 23.08
Updated Date 08/29/2025
52 Weeks Range 11.56 - 23.08
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.89

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -7957.09%

Management Effectiveness

Return on Assets (TTM) -29.71%
Return on Equity (TTM) -83.96%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 657551736
Price to Sales(TTM) 1120.01
Enterprise Value 657551736
Price to Sales(TTM) 1120.01
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.47
Shares Outstanding 52335800
Shares Floating 40921330
Shares Outstanding 52335800
Shares Floating 40921330
Percent Insiders 6.31
Percent Institutions 31.11

ai summary icon Upturn AI SWOT

Oculis Holding AG Ordinary shares

stock logo

Company Overview

overview logo History and Background

Oculis Holding AG is a biopharmaceutical company focused on developing innovative ophthalmic treatments. Founded in 2003, they have reached milestones in developing topical formulations to treat various eye diseases, shifting away from injected approaches.

business area logo Core Business Areas

  • Dry Eye Disease: Developing licaminlimab (OCS-01), a topical antibody fragment, for the treatment of dry eye disease.
  • Diabetic Macular Edema (DME): Developing OCS-02, a topical anti-TNFu03b1 antibody, for the treatment of DME.
  • Neuro-retina: Developing OCS-05 for Neuro-retina indications such as optic neuritis.

leadership logo Leadership and Structure

Riad Sherif is the Chief Executive Officer. The company operates with a management team overseeing research, clinical development, and commercial strategy. A board of directors provides governance and strategic oversight.

Top Products and Market Share

overview logo Key Offerings

  • Licaminlimab (OCS-01): A topical antibody fragment being developed for Dry Eye Disease (DED). Market share is pre-launch, expected to compete with products like Xiidra and Restasis, and Miebo. Competitors: Novartis (Xiidra), AbbVie (Restasis), Bausch + Lomb (Miebo).
  • OCS-02: A topical anti-TNFu03b1 antibody being developed for Diabetic Macular Edema (DME). Market share is pre-launch. Competitors: Regeneron (Eylea), Roche (Vabysmo), Novartis (Beovu).
  • OCS-05: Under development for Neuro-retina applications such as optic neuritis. Market share is pre-launch. Competitors are limited due to novel approach. Treatment would be competing with steroids.

Market Dynamics

industry overview logo Industry Overview

The ophthalmic market is experiencing growth due to an aging population and increased prevalence of eye diseases. Innovation is focused on topical treatments and novel therapies.

Positioning

Oculis aims to disrupt the ophthalmic market with topical alternatives to injected therapies, potentially offering improved patient convenience and compliance.

Total Addressable Market (TAM)

The global ophthalmology market is estimated to be over $40 billion and growing. Oculis's positioning targets significant portions of this TAM with its lead products, especially in DED and DME.

Upturn SWOT Analysis

Strengths

  • Novel topical formulations
  • Potential for improved patient compliance
  • Experienced management team
  • Strong clinical pipeline

Weaknesses

  • Dependence on clinical trial outcomes
  • Pre-revenue company
  • Competition from established players
  • Manufacturing and regulatory risks

Opportunities

  • Expansion into new ophthalmic indications
  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Growing ophthalmic market

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from generics
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • NOVN (Novartis)
  • ABBV (AbbVie)
  • SNY (Sanofi)
  • REGN (Regeneron)
  • RHHBY (Roche)

Competitive Landscape

Oculis seeks to gain market share with topical medications competing with existing therapies, including injectables. They benefit from novel formulations but face competition from established players with strong market presence and brand recognition.

Growth Trajectory and Initiatives

Historical Growth: Focus is on clinical development and progressing through trial phases.

Future Projections: Growth is dependent on the successful commercialization of its lead drug candidates. Analyst estimates pending commercialization.

Recent Initiatives: Advancing OCS-01 and OCS-02 through Phase 3 trials, exploring new indications.

Summary

Oculis is a pre-revenue biopharmaceutical company with a promising pipeline of topical ophthalmic treatments. The company's success hinges on the outcomes of its late-stage clinical trials. It faces challenges from established competitors, however the topical delivery may present a paradigm shift in opthalmology, and has the potential to transform patient outcomes with new formulations. Key areas to monitor are clinical trial results, regulatory approvals, and market access strategies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Investor Presentations
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated. Investing in pharmaceutical companies carries significant risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Oculis Holding AG Ordinary shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-03-02
CEO & Director Dr. Riad Sherif M.B.A., M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 49
Full time employees 49

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.